Project Grant R43HL182462
Award Date 9/10/25
Completion Date 9/9/26
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philomath, OR 97370, USA
Similar Awards
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded Fluidform Inc. a $766,107 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) from April 1, 2021 to March 31, 2022. The grant funds the development of an advanced bioprosthetic collagen heart valve using 3D printing techniques to recreate the collagen fiber architecture and mechanical properties of native heart valve leaflets. Fluidform will collaborate with Carnegie Mellon...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- The National Heart Lung and Blood Institute (NHLBI), part of the U.S. National Institutes of Health (NIH), awarded a $460,625 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University on August 10, 2025. The objective of this project is to develop highly tunable and customizable Tissue Engineered Vascular Conduits (TEVCs) using a novel bioprinting method that can directly print fully physiological materials, including cell-laden tissues. The project aims...
- This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
- The federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $865,286 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop a high-resolution spatiotemporal lineage map of cardiac development. The research aims to spatiotemporally map early cardiac progenitor lineages and their clonal relationships, map the phylogeny of major myocardial cell...
- This $321,679 Project Grant, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development and testing of an expandable pediatric pulmonary heart valve device. The research aims to create a valve that can grow larger with the patient to address the challenge of multiple open-heart surgeries required for infants and children with severe heart valve defects. The key research activities include optimizing the...
- The federal Project Grant award, valued at $413,595, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports the development of a "Magnetic Rotational Platform for Coronary Lesions" by Unandup, LLC, a technology firm in St. Louis, Missouri. The project aims to create an innovative medical device technology that leverages magnetic fields to improve the treatment of severe coronary artery...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $443,544 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Dasisimulations LLC, a minority-owned small business located in Dublin, Ohio. The grant supports the development and validation of an innovative, AI-driven software platform to automatically perform complex measurements for pre-planning transcatheter aortic valve replacement (TAVR) procedures. The project aims to (1) develop and validate the...
- This $298,368 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a novel device for treating mitral valve regurgitation. The project aims to optimize the device design and procedure through bench testing, followed by acute in vivo studies to demonstrate the feasibility of the approach. The funding recipient, Link Medical LLC, has invented a catheter-based technology intended to restore proper mitral...